Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Sutherland

Showing results (251-260 of 271) with videos related to

Pageof 28
Sort By:
Genomics|January 15, 1997
Cloning and sequencing of the mouse Gli2 gene: localization to the Dominant hemimelia critical regionD C Hughes, J Allen, G Morley, et al.
Medical Physics|May 19, 2017
MO-F-213AB-04: Biological Effect of Dose Shadowing by Fiducial Markers in Spot Scanning Proton Therapy with a Limited Number of FieldsT Matsuura, K Maeda, K Sutherland, et al.
Plos One|September 15, 2023
Geospatial availability of breast cancer treatment modalities and hypothetical access improvement in Ghana: A nationwide surveySarah Schoenhals, Meghan E Mali, Edward K Sutherland, et al.
Biological & Pharmaceutical Bulletin|March 21, 2001
The biological activities of 1alpha,25-dihydroxyvitamin D3 and its synthetic analog 1alpha,25-dihydroxy-16-ene-vitamin D3 in normal human osteoblastic cells and human osteosarcoma SaOS-2 cells are modulated by 17-beta estradiol and dependent on stage of differentiationL G Rao, L J Liu, M R Rawlins, et al.
Plos One|August 14, 2024
Availability and geographic access to breast cancer pathology services in GhanaMatthew D Price, Meghan E Mali, Adjei Ernest, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 2021
Survival predictors of <sup>177</sup>Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)Mina M Swiha, Duncan E K Sutherland, Golmehr Sistani, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2025
Intussusceptive angiogenesis-on-a-chip: Evidence for transluminal vascular bridging by endothelial delaminationSabrina C R Staples, Hao Yin, Frances S K Sutherland, et al.
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
British Journal of Cancer|July 29, 2010
Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75M C Ryan, H Kostner, K A Gordon, et al.
The Biochemical Journal|July 27, 1999
Solution structure of a defensin-like peptide from platypus venomA M Torres, X Wang, J I Fletcher, et al.
Pageof 28

Showing results (251-260 of 271) with videos related to

Sort By:
Pageof 28
Genomics|January 15, 1997
Cloning and sequencing of the mouse Gli2 gene: localization to the Dominant hemimelia critical regionD C Hughes, J Allen, G Morley, et al.
Medical Physics|May 19, 2017
MO-F-213AB-04: Biological Effect of Dose Shadowing by Fiducial Markers in Spot Scanning Proton Therapy with a Limited Number of FieldsT Matsuura, K Maeda, K Sutherland, et al.
Plos One|September 15, 2023
Geospatial availability of breast cancer treatment modalities and hypothetical access improvement in Ghana: A nationwide surveySarah Schoenhals, Meghan E Mali, Edward K Sutherland, et al.
Biological & Pharmaceutical Bulletin|March 21, 2001
The biological activities of 1alpha,25-dihydroxyvitamin D3 and its synthetic analog 1alpha,25-dihydroxy-16-ene-vitamin D3 in normal human osteoblastic cells and human osteosarcoma SaOS-2 cells are modulated by 17-beta estradiol and dependent on stage of differentiationL G Rao, L J Liu, M R Rawlins, et al.
Plos One|August 14, 2024
Availability and geographic access to breast cancer pathology services in GhanaMatthew D Price, Meghan E Mali, Adjei Ernest, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 2021
Survival predictors of <sup>177</sup>Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)Mina M Swiha, Duncan E K Sutherland, Golmehr Sistani, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2025
Intussusceptive angiogenesis-on-a-chip: Evidence for transluminal vascular bridging by endothelial delaminationSabrina C R Staples, Hao Yin, Frances S K Sutherland, et al.
Therapeutic Advances in Medical Oncology|June 16, 2023
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature reviewDuncan E K Sutherland, Raghava Kashyap, Price Jackson, et al.
British Journal of Cancer|July 29, 2010
Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75M C Ryan, H Kostner, K A Gordon, et al.
The Biochemical Journal|July 27, 1999
Solution structure of a defensin-like peptide from platypus venomA M Torres, X Wang, J I Fletcher, et al.
Pageof 28